

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness, and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Touyun Biotech Group Limited
透雲生物科技集團有限公司
(Incorporated in Bermuda with limited liability)
(Stock Code: 1332)

POSITIVE PROFIT ALERT

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of Touyun Biotech Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rules 13.09 of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) and the Inside Information Provisions (as defined under the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The Board wishes to inform the shareholders of the Company (the “**Shareholders**”) and potential investors that, based on its preliminary assessment of the Group’s unaudited consolidated management accounts for the six months ended 30 June 2026 (the “**Reporting Period**”), the Group is expected to record a profit and total comprehensive income attributable to owners of the Company in the range of approximately HK\$180 million to HK\$200 million, representing an increase of approximately 1,025% to 1,150% as compared to a profit and total comprehensive income attributable to owners of the Company of approximately HK\$16 million for the corresponding period last year. Based on the information available to date, the expected increase in the profit was mainly attributable to the Group recorded a fair value gain on financial assets at fair value through profit or loss on unlisted and listed equity investment of approximately HK\$340 million compared with the fair value gain of approximately HK\$73 million for the six months ended 30 June 2025.

The information contained in this announcement is only based on the preliminary assessment by the Company’s management which is based on the latest financial information of the Group available to the management. The above information may be subject to further adjustments based on further updated information, and following the review of the Company’s audit committee of the Board. Shareholders and potential investors of the Company are advised to refer to the results announcement of the Company for the Reporting Period, which will be published by the Company on or before the end of August 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Touyun Biotech Group Limited
Wang Liang
Chairman

Hong Kong, 26 August 2026

As at the date of this announcement, the Board comprised:

Executive Directors

Mr. Wang Liang (*Chairman*)
Ms. Zhou Ruijuan (*Vice Chairlady*)
Mr. Du Dong

Non-executive Directors

Mr. Chen Hui
Ms. Tian Yuze
Mr. Zhang Lele

Independent Non-executive Directors

Mr. Cheung Wing Ping
Mr. Ha Kee Choy Eugene
Mr. To Shing Chuen